These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9617437)

  • 1. Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis.
    Wetzig T; Petri JB; Mittag M; Haustein UF
    Arch Dermatol Res; 1998 Apr; 290(4):187-90. PubMed ID: 9617437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble P selectin in systemic sclerosis: relationship with von Willebrand factor, autoantibodies and diffuse or localised/limited disease.
    Blann AD; Constans J; Carpentier P; Renard M; Satger B; Guérin V; Boisseau MR; Neau-Cransac N; Conri C
    Thromb Res; 2003 Feb; 109(4):203-6. PubMed ID: 12757775
    [No Abstract]   [Full Text] [Related]  

  • 3. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis.
    Liakouli V; Manetti M; Pacini A; Tolusso B; Fatini C; Toscano A; Cipriani P; Guiducci S; Bazzichi L; Codullo V; Ruocco L; Dell'orso L; Carubbi F; Marrelli A; Abbate R; Bombardieri S; Ferraccioli G; Montecucco C; Valentini G; Matucci-Cerinic M; Ibba-Manneschi L; Giacomelli R
    Ann Rheum Dis; 2009 Apr; 68(4):584-90. PubMed ID: 18445624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
    Simon D; Czömpöly T; Berki T; Minier T; Peti A; Tóth E; Czirják L; Németh P
    Int Immunol; 2009 Apr; 21(4):415-22. PubMed ID: 19211583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
    Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
    Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of soluble Fas ligand in patients with silicosis.
    Tomokuni A; Otsuki T; Isozaki Y; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
    Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease.
    Cordiali-Fei P; Mussi A; D'Agosto G; Trento E; Bordignon V; Trincone S; Vento A; Sperduti I; Cristaudo A; Ensoli F
    Clin Dev Immunol; 2013; 2013():390563. PubMed ID: 23818915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological profile of patients with systemic sclerosis.
    Wielosz E; Dryglewska M; Majdan M
    Postepy Hig Med Dosw (Online); 2014 Aug; 68():987-91. PubMed ID: 25228505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.
    Meyer OC; Fertig N; Lucas M; Somogyi N; Medsger TA
    J Rheumatol; 2007 Jan; 34(1):104-9. PubMed ID: 17117486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?
    Diot E; Giraudeau B; Diot P; Degenne D; Ritz L; Guilmot JL; Lemarié E
    Chest; 1999 Sep; 116(3):715-20. PubMed ID: 10492277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
    Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
    Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.
    Chang WS; Schollum J; White DH; Solanki KK
    Clin Rheumatol; 2015 Nov; 34(11):1921-7. PubMed ID: 26022620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
    Hamaguchi Y
    J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis.
    Wuttge DM; Carlsen AL; Teku G; Steen SO; Wildt M; Vihinen M; Hesselstrand R; Heegaard NH
    Rheumatology (Oxford); 2015 Nov; 54(11):2100-7. PubMed ID: 26163687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis.
    Garcia-Velasco JA; Mulayim N; Kayisli UA; Arici A
    Fertil Steril; 2002 Oct; 78(4):855-9. PubMed ID: 12372468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.
    Yanaba K; Takehara K; Sato S
    Ann Rheum Dis; 2004 May; 63(5):583-7. PubMed ID: 15082492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?
    Benyamine A; Bertin D; Heim X; Granel B; Bardin N
    Eur J Intern Med; 2017 Oct; 44():e42-e44. PubMed ID: 28781194
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
    Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
    J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study.
    Kranenburg P; van den Hombergh WM; Knaapen-Hans HK; van den Hoogen FH; Fransen J; Vonk MC
    Rheumatology (Oxford); 2016 Nov; 55(11):2001-2008. PubMed ID: 27520796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.